Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia
Authors:
Open Access
- 31 January 2015
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (8) , 6448-6458
Abstract
Purpose: This prospective phase II, open label, study was designed to assess the efficacy and safety of D-CAG induction treatment for elderly patients with newly diagnosed AML.Keywords
This publication has 33 references indexed in Scilit:
- Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicinLeukemia, 2012
- Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemiaBlood, 2012
- Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AMLBlood, 2011
- A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndromeHaematologica, 2011
- Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acidClinical Epigenetics, 2011
- FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyBlood, 2010
- Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2010
- DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic SyndromesJournal of Clinical Oncology, 2010
- Hematopoietic cell transplantation–specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiencesBlood, 2007
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003